The Oncology Shot with Timothee Olivier
The Oncology Shot with Timothee Olivier
HomeNotesResearch & PublicationsArchiveAbout
Sign in

The PATINA trial – palbociclib maintenance in…

Timothée Olivier
Feb 8

What is the best 1st-line strategy in patients with HR+/HER2+ advanced/metastatic breast cancer?

Read →
3 Comments
User's avatar
Sahar van Waalwijk's avatar
Sahar van Waalwijk
Feb 8

Brilliant analysis... I’ve just read the paper, and one thing is rather puzzeling. They write: “The trial was powered [ ] on the assumption of a median progression‑free survival of 13.0 months in the standard‑therapy group and 19.5 months in the palbociclib group.” This assumption is somewhat surprising, because these medians are very close to those reported years ago in CLEOPATRA (PFS 12.4 m with placebo vs 18.7 m with pertuzumab). In other words, their expected PFS for both arms is much shorter than what one would expect.... This is while PATINA recruited "induction-responder population" (so more favourable biology), with almost twice as many HR+ patients as in CLEOPATRA... all these should increase PFS rather than shorten it... So why do they predict such low PFS in their hypothesis?

Like (3)
Reply (1)
Share
Sietse's avatar
Sietse
Feb 22

PFS was measured from randomization, not from start of first-line therapy.

Like (1)
Reply
Share
Michelino De Laurentiis's avatar
Michelino De Laurentiis
Feb 12

Thank you for this thoughtful and carefully argued appraisal of the PATINA trial. The discussion on informative censoring is particularly important, as this issue often receives less attention than it deserves in oncology trials.

While the trial provides valuable clinical insights, analyses like yours remind us that methodological nuances can meaningfully influence interpretation. Constructive scrutiny of these aspects is essential if we aim to strengthen the design and credibility of future studies.

At the same time, it is important to recognize that this remains a hypothesis-generating perspective, and alternative interpretations may reasonably emerge as the data are further examined and debated.

Thank you again for offering such a stimulating and intellectually honest perspective. I look forward to your continued exploration of these methodological issues, as this kind of critical reflection is invaluable to the oncology community.

Like (1)
Reply
Share
The Oncology Shot with Timothee Olivier

My Personal Substack

  • About
  • Archive
  • Sitemap
© 2026 Timothée Olivier · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.